Geneticure

Geneticure operates in the precision medicine diagnostics sector, focusing on the massive and underserved global hypertension market. The company's proprietary multi-gene algorithm analyzes patient DNA to predict response to various blood pressure medications, aiming to replace the standard trial-and-error approach with a genetically-guided first-line therapy. Backed by research published in peer-reviewed journals and notable investors like the Mayo Clinic, Geneticure's commercial test is designed to improve patient outcomes, reduce cardiovascular events, and lower overall healthcare costs. The company is privately held and appears to be in an early revenue stage, commercializing its diagnostic directly to patients and clinicians.

Patented multi-gene pharmacogenomic algorithm analyzing 11 genes and 17 genotypes to predict patient response to antihypertensive drug classes and guide personalized treatment selection.

Geneticure competes in the pharmacogenomics testing space, where competitors include companies like OneOme (owned by Mayo Clinic and UnitedHealth), Genomind, and GeneSight, though these often focus on psychiatry. Larger clinical labs (Quest, LabCorp) also offer some pharmacogenomic panels. Direct competition in hypertension-specific multi-gene guided therapy is emerging but not yet crowded, giving Geneticure a potential first-mover advantage in this niche.